News
EBS
8.10
+0.50%
0.04
Emergent BioSolutions receives $50M contract option from BARDA
TipRanks · 5d ago
Weekly Report: what happened at EBS last week (1209-1213)?
Weekly Report · 5d ago
War On Drugs 'Has Failed, Completely And Utterly': UN High Commissioner Urges Evidence-Based Solutions
Benzinga · 12/09 16:30
Weekly Report: what happened at EBS last week (1202-1206)?
Weekly Report · 12/09 09:15
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) lost 9.5% last week but have reaped the benefits of longer-term growth
Simply Wall St · 12/06 11:04
Why Emergent BioSciences Stock Plummeted Today
NASDAQ · 12/03 23:47
SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook
Seeking Alpha · 12/02 22:49
Weekly Report: what happened at EBS last week (1125-1129)?
Weekly Report · 12/02 09:15
Weekly Report: what happened at EBS last week (1118-1122)?
Weekly Report · 11/25 09:14
WHO extends mpox emergency; Canada reports first Clade I case
Seeking Alpha · 11/23 19:48
Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement
Benzinga · 11/22 20:31
WHO determines mpox upsurge still constitutes public health emergency
TipRanks · 11/22 17:55
World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern
Benzinga · 11/22 17:43
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks
Barchart · 11/22 14:10
Weekly Report: what happened at EBS last week (1111-1115)?
Weekly Report · 11/18 09:13
First mpox case linked to African outbreak reported in U.S.
Seeking Alpha · 11/17 06:50
Vaccine stocks drop on concerns about RFK Jr. heading HHS
Seeking Alpha · 11/15 16:53
Vaccines makers close lower on reports RFK Jr may head HHS
Seeking Alpha · 11/14 21:45
Emergent BioSolutions files to sell 3.61M shares of common stock for holders
TipRanks · 11/12 21:13
After Trump's Win, It's Time To Take Profits On Gold
Benzinga · 11/11 13:33
More
Webull provides a variety of real-time EBS stock news. You can receive the latest news about Emergent Biosolutions Inc through multiple platforms. This information may help you make smarter investment decisions.
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.